Browsing by Author "Cortés, J"

Now showing 1 - 3 of 3

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
(Elsevier Ltd., 2020) Cardoso, F; Paluch-Shimon, S; Senkus, E; Curigliano, G; Aapro, MS; André, F; Barrios, CH; Bergh, J; Bhattacharyya, GS; Biganzoli, L; Boyle, F; Cardoso, MJ; Carey, LA; Cortés, J; El Saghir, NS; Elzayat, M; Eniu, A; Fallowfield, L; Francis, PA; Gelmon, K; Gligorov, J; Haidinger, R; Harbeck, N; Hu, X; Kaufman, B; Kaur, R; Kiely, BE; Kim, SB; Lin, NU; Mertz, SA; Neciosup, SO; ffersen, BV; Ohno, S; Pagani, O; Prat, A; Penault-Llorca, F; Rugo, HS; Sledge, GW; Thomssen, C; Vorobiof, DA; Wiseman ,T; Xu, B; Norton, L; Costa, A; Winer, EP
This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients. It provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care. Updated diagnostic and treatment algorithms are also provided. All recommendations were compiled by a multidisciplinary group of international experts. Recommendations are based on available clinical evidence and the collective expert opinion of the authors.
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer
(Taylor and Francis Ltd., 2024) Turner, NC; Oliveira, M; Howell, SJ; Dalenc, F; Cortés, J; Gomez, HL; Hu, X; Jhaveri, K; Krivorotko, P; Loibl, S; Murillo, SM; Park, YH; Sohn, J-H; Toi, M; Tokunaga, E; Yousef, S; Zhukova, L; de, Bruin, E; Grinsted, L; Schiavon, G; Foxley, A; Rugo, HS
What is this summary about?: This is a summary of the article discussing the results of the CAPItello-291 study. In the study, participants had advanced breast cancer that could not be completely removed with surgery, and that was diagnosed as a type of breast cancer where tumor cells had hormone receptors (HR-positive) but did not have HER2 receptors (HER2-negative). All participants were also required to have previously received treatment with a type of therapy called an aromatase inhibitor (with or without a CDK4/6 inhibitor), but over time their cancer cells had still grown or spread. The CAPItello-291 study researchers wanted to find out if a treatment combination of the medications capivasertib plus fulvestrant worked better than placebo plus fulvestrant. Capivasertib is a drug that blocks the activity of a protein called AKT, which is found inside breast cancer cells. What are the key takeaways?: The main finding was that participants who took capivasertib plus fulvestrant lived longer without their disease getting worse (progressing) compared with those treated with placebo plus fulvestrant. This is called progression-free survival. This result was seen across all participants (median progression-free survival of 7.2 months with capivasertib plus fulvestrant vs 3.6 months with placebo plus fulvestrant). It was also seen in participants whose tumors had detectable genetic alterations in genes called PIK3CA, AKT1, and/ or PTEN (median progression-free survival of 7.3 months with capivasertib plus fulvestrant vs 3.1 months with placebo plus fulvestrant). The most common side effects experienced by participants included diarrhea and different types of rash. These were as expected (given how capivasertib works). The CAPItello-291 study is still ongoing, and more results are expected to be released in the future. What were the main conclusions reported by the researchers?: Results from the CAPItello-291 study showed that capivasertib plus fulvestrant compared with placebo plus fulvestrant improved progression-free survival in participants with HR-positive/ HER2-negative advanced breast cancer whose cancer had grown or spread despite hormone therapy (with/without a CDK4/6 inhibitor). Clinical Trial Registration:NCT04305496 (CAPItello-291) (ClinicalTrials.gov).
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
(American Association for Cancer Research Inc., 2018) Sharma, P; López-Tarruella, S; García-Saenz, JA; Khan, QJ; Gómez, HL; Prat, A; Moreno, F; Jerez-Gilarranz, Y; Barnadas, A; Picornell, AC; Monte-Millán MD; González-Rivera, M; Massarrah, T; Pelaez-Lorenzo, B; Palomero, MI; González Del Val, R; Cortés, J; Fuentes-Rivera H; Morales, DB; Márquez-Rodas, I; Perou, CM; Lehn, C; Wang, YY; Klemp, JR; Mammen, JV; Wagner, JL; Amin, AL; O'Dea, AP; Heldstab, J; Jensen, RA; Kimler, BF; Godwin, AK; Martín, M
Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathologic response in patients treated with carboplatin plus docetaxel NAC. Patients and methods: One-hundred and ninety patients with stage I-III TNBC were treated with neoadjuvant carboplatin (AUC6) plus docetaxel (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence of invasive tumor in breast and axilla) and Residual cancer burden (RCB) were evaluated. Patients were followed for recurrence and survival. Extent of pathologic response was associated with RFS and OS using the Kaplan-Meier method. Results: Median age was 51 years, and 52% were node-positive. pCR and RCB I rates were 55% and 13%, respectively. Five percent of pCR patients, 0% of RCB I patients, and 58% of RCB II/III patients received adjuvant anthracyclines. Three-year RFS and OS were 79% and 87%, respectively. Three-year RFS was 90% in patients with pCR and 66% in those without pCR [HR = 0.30; 95% confidence interval (CI), 0.14-0.62; P = 0.0001]. Three-year OS was 94% in patients with pCR and 79% in those without pCR (HR = 0.25; 95% CI, 0.10-0.63; P = 0.001). Patients with RCB I demonstrated 3-year RFS (93%) and OS (100%) similar to those with pCR. On multivariable analysis, higher tumor stage, node positivity, and RCB II/III were associated with worse RFS. Conclusions: Neoadjuvant carboplatin plus docetaxel yields encouraging efficacy in TNBC. Patients achieving pCR or RCB I with this regimen demonstrate excellent 3-year RFS and OS without adjuvant anthracycline.